Clinigen Group plc Issue of Equity (9810M)
21 October 2016 - 6:00PM
UK Regulatory
TIDMCLIN
RNS Number : 9810M
Clinigen Group plc
21 October 2016
21 October 2016
Issue of Equity
Clinigen Group plc (the "Group", AIM: CLIN) announces that it
has made an application for the admission to trading on AIM of
388,771 ordinary shares of 0.1 pence each in the Group (the "New
Ordinary Shares"), which have been issued to satisfy the exercise
of share options and rank pari passu with the existing shares of
the Group. Admission to trading on AIM of the New Ordinary Shares
is anticipated to occur on 24 October 2016.
At admission the issued share capital of the Group will consist
of 115,094,263 ordinary shares, with no shares held in treasury.
The total number of voting rights in the Group will therefore be
115,094,263. This figure may be used by shareholders as the
denominator to determine if they are required to notify their
interests in, or a change to their interest in, the Group under the
Disclosure and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283
495010
Shaun Chilton, Group Chief
Executive Officer-designate
Martin Abell, Group Chief
Financial Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
Peel Hunt LLP Tel: +44 (0) 20
7418 8900
James Steel / Dr Christopher
Golden
Instinctif Partners Tel: +44 (0) 20
7457 2020
Adrian Duffield / Melanie
Toyne-Sewell / Jayne Crook Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programs
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
commercial products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEFFLFLUFMSEES
(END) Dow Jones Newswires
October 21, 2016 03:00 ET (07:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024